Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK
Partnership to Enable Broader Collaboration in China
Cytovia Therapeutics, Inc., a biopharmaceutical
company developing allogeneic “off-the-shelf” gene-edited iNK (NK
cells derived from iPSC) and CAR (Chimeric Antigen Receptor)
Natural Killer (NK) cells derived from induced pluripotent stem
cells (iPSCs) and Flex-NK™ cell engager multifunctional antibodies,
and
Cellectis (Euronext Growth: ALCLS -
Nasdaq: CLLS), a clinical-stage gene-editing company employing its
core technology to develop products based on gene-editing with a
portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in
the field of immuno-oncology and gene-edited hematopoietic stem
cells in other indications, announced today that they have expanded
their collaboration of TALEN® gene-edited iPSC-derived NK and
CAR-NK cells to include new CAR target and development in China by
Cytovia’s joint venture entity, CytoLynx Therapeutics.
The amended financial terms include an equity
stake totaling $20 million in Cytovia stock as well as up to $805
million of development, regulatory, and sales milestones and
single-digit royalty payments on the net sales of all partnered
products commercialized by Cytovia.
“We are pleased to expand the collaboration with
Cellectis to enable Cytovia to develop iNK products that will
leverage the high-precision of TALEN® to perform gene-editing to
minimize the risk of off-target effects and unlock the full
potential of NK cells as a first line of defense against cancer.
Cytovia’s internal research and development, and manufacturing
teams are actively developing multiple gene-edited therapeutic
candidates and optimizing our technology platform towards next
generation products,” said Dr. Daniel Teper, Chairman & CEO of
Cytovia Therapeutics.
Cellectis is developing custom TALEN®, which
Cytovia uses to edit iPSCs. Cytovia is responsible for the
differentiation and expansion of the gene-edited iPSC master cell
bank into NK cells and is conducting the pre-clinical evaluation,
clinical development, and commercialization of the
mutually-agreed-upon selected therapeutic candidates. Cellectis is
granting Cytovia a worldwide license under the patent rights over
which Cellectis has the control in this field, including in
China, enabling Cytovia to modify NK cells to address multiple
gene-targets for therapeutic use in several cancer indications.
“We are thrilled at the progress Cytovia has
accomplished in the past year,” said Dr. André Choulika, CEO of
Cellectis. “Cytovia has attracted a world-class scientific team and
is advancing its clinical candidates in areas of significant unmet
medical need, sharing Cellectis’ mission to provide life-saving
off-the-shelf allogeneic cell therapy to patients.”
About Cytovia TherapeuticsCytovia Therapeutics
aims to accelerate patient access to transformational cell
therapies and immunotherapies, addressing several of the most
challenging unmet medical needs in cancer.
Cytovia focuses on harnessing the innate immune
system by developing complementary and disruptive NK-cell and
NK-engager antibody platforms. It is developing three types of
iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-edited
iNK cells with improved function and persistence, and TALEN®
gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to
improve tumor-specific targeting. The second complementary
cornerstone technology is a quadrivalent multifunctional antibody
platform designed to engage natural killer cells by targeting NKp46
using its proprietary Flex-NK™ technology.
These two technology platforms are being used to
develop treatment of patients with solid tumors such as
hepatocellular carcinoma (HCC) and glioblastoma as well as
hematological malignancies such as refractory multiple
myeloma.
Cytovia’s research and development laboratories
in Natick, MA and GMP cell manufacturing facility in Puerto Rico
are augmented by scientific partnerships with Cellectis,
CytoImmune, the Hebrew University of Jerusalem, INSERM, the New
York Stem Cell Foundation, and the University of California San
Francisco (UCSF).
Cytovia Therapeutics has recently
formed CytoLynx Therapeutics, a joint-venture entity
focused on research and development, manufacturing, and
commercialization activities in Greater China and beyond.
Find out more at www.cytoviatx.com
About Cellectis Cellectis
is a gene editing company, developing first of its kind therapeutic
products. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to achieve therapeutic gene editing
in hemopoietic stem cells for various genetic disorders. As a
clinical-stage biopharmaceutical company with over 21 years of
expertise in gene editing, Cellectis is developing life-changing
cell therapy product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation
system in order to treat diseases with unmet medical
needs.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing lifesaving UCART product
candidates for multiple cancers including acute myeloid leukemia
(AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple
myeloma (MM). .HEAL is a new platform focusing on
hemopoietic stem cells to treat blood disorders, immunodeficiencies
and lysosomal storage diseases.
Cellectis headquarters are in Paris, France,
with locations in New York City, New York and Raleigh, North
Carolina. Cellectis is listed on the Nasdaq Global Market (ticker:
CLLS) and on Euronext Growth (ticker: ALCLS).
For more information,
visit www.cellectis.comFollow Cellectis on social media:
@cellectis, LinkedIn and YouTube.
For further information on Cellectis,
please contact:
Media contacts: Margaret Gandolfo, Senior
Manager, Communications, +1 (646) 628 0300 Pascalyne
Wilson, Director, Communications, +33776991433,
media@cellectis.com
Investor relation
contact: Eric Dutang, Chief Financial
Officer, +1 (646) 630
1748, investor@cellectis.com
For further information on Cytovia
Therapeutics, please contact:
Investor contact:Anna Baran-DjokovicVP,
Investor Relations and Capital Marketsanna@cytoviatx.com+1 (305)
615 9162
Media contact:Sophie BadréVP, Corporate
Affairssophie.badre@cytoviatx.com +1 (929) 317-1565
Shani LewisLaVoieHealthScienceslewis@lavoiehealthscience.com+1
(609) 516-5761
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as “at
this time,” “anticipate,” “believe,” “expect,” “on track,” “plan,”
“scheduled,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, include statements
about our research and development projects and priorities, our
pre-clinical project development efforts and the timing of our
presentation of data. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development as well as the duration and severity of the COVID-19
pandemic and governmental and regulatory measures implemented in
response to the evolving situation. With respect to our cash
runway, our operating plans, including product development plans,
may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2020 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- FINAL_PR_CytoviaTx_Cellectis_Partnership_Nov 18 2021_.pdf
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024